anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic Fatigue Syndrome (CFS) is a serious, complex and extremely debilitating chronic illness, but often misunderstood characterized by prolonged fatigue, the hallmark of the condition and multiple nonspecific symptoms. The World Health Organization has recognized CFS as a disease that affecting the nervous system (ICD-10 G93.3) and multiple body systems. The etiology is unknown. Previous studies have demonstrated in CFS patients a significant reduction in plasma and intracellular Peripheral Blood Mononuclear Cells concentrations of Coenzyme Q10 and NADH, which correlate with clinical symptoms of the disease. Hypothesis: Supplementation with CoQ10 plus NADH could be beneficial in the improvement of clinical and molecular parameters in this disease. The primary endpoint is to evaluate the efficacy of oral Reconnect ® suplementation on the maximum heart rate changes during an exercise test in CFS. The secondary endpoints are to evaluate the effect of Reconnect ® suplementation on perception of fatigue (assessed by FIS), pain (McGill Pain Index Questionnaire), and sleep disruption (Pittsburgh Sleep Index Questionnaire).

Patients and Methods: A total of 80 consecutive women patients with a diagnosis of CFS according to the 1994 CDC Fukuda's definition criteria were initially evaluated and enrolled in this study. The majority were excluded for no meet the inclusion criteria of the study. All subjects are treatment with ReConnect® containing CoQ10 plus NADH versus placebo. Fatigue levels, pain and sleep disturbances are scored using the Fatigue Impact Scale, McGill Pain Questionnaire and Pittsburgh Sleep Quality Index, respectively.

Discussion: To our knowledge, no previous studies have yet evaluated the effectiveness of oral ReConnect supplementation in CFS. ReConnect containing the combination of CoQ10 plus NADH and other nutrients (phosphoserine and Vitamin C) can help to improve clinical symptoms and restore mitochondrial function and oxidative stress reducing fatigue, pain and sleep impairments in CFS. The combination of these supplements can result in a safe and effective therapy to reduce fatigue, pain and improve sleep as well help restore quality of life of CFS patients.
Patients will receive the PBMT from the first day of RT, 5 times a week (Monday to Friday), for 6 to 7 weeks, or until there are no more mucositis lesions, just before the RT session. Intraoral protocol will utilize a low-level laser device (MMOptics Ltda, Sao Carlos, Sao Paulo, Brazil) with wavelength 660nm, power 100 mW, spot 0.03 cm², dose 10 J/cm², and time 3 seconds. The irradiations will be punctual and in a contact form, with 1 cm between the points, perpendicular to the oral mucosa, avoiding the tumor site and will be performed: 6 points on the labial mucosa (3 in the upper and 3 in the lower), 2 points on the labial commissure (1 on the right and 1 on the left), 8 points on the jugal mucosa (4 on the right and 4 on the left), 8 points on the lateral border of the tongue (4 on the right and 4 on the left), 5 points on the ventral tongue (2 on the right, 2 on the left side and 1 point on the apex), 4 points on the oral floor (2 on the right and 2 on the left side).
A key component of the multimodal approach to pain management is the intra-operative surgical site injection of a local anesthetic or drug cocktail. There are many formulations used for this purpose. A formulation documented in the literature was implemented by this institution which has dropped the average length of stay dramatically. Concern over the limited half-life of the administered anesthetic and the continued need for opioid administration has led to a search for better drug formulations and administration vehicles. Recently, the FDA approval of an extended release bupivacaine called liposomal bupivacaine was thought to extend the effective half-life of the anesthetic agent and thereby prolong post-operative anesthesia. Use of liposomal bupivacaine in total joint surgery was almost universally adopted after its recent approval and has been an integral part of the "same day total joint" movement.

Studies have suggested improvement in pain control and shortened hospitalizations with the use of liposomal bupivacaine. Other studies have raised questions about the effectiveness of this agent. Recently a randomized double blind study was performed with total knees which demonstrated no improvement in pain management with the addition of liposomal bupivacaine to the multimodal pain management protocol. This study has not been performed in the hip arthroplasty population.
The invention belongs to the technical field of traditional Chinese medicines and relates to Radix Astragali extract and its preparation method and preparation. The Radix Astragali extract is used for treating shortness of breath, palpitaition, collapse, spontaneous perspiration, asthenia and edema, symptoms after tumor chemoradiotherapy and operation, chronic nephrosis, chronic diarrhea, proctoptosia, uterine prolapsed, gynecological diseases, ulcer fester and nonunion wounds. The Radix Astragali extract has obviously improved content of total saponins and astragaloside. The preparation method comprises the following steps of adding water into Radix Astragali, carrying out decoction, filtering the decoction, concentrating the filtrate, adding ethanol into the concentrated filtrate, carrying out standing, collecting a supernatant, recovering the ethanol, carrying out condensation and drying, and carrying out crushing to obtain fine powder. Aiming at solving defects of the existing preparation and satisfying clinical medicine requirements, the inventor carries out detailed research. The Radix Astragali extract as an active component and appropriate medicinal auxiliary materials are processed into the preparation by the conventional processes.
1413851 α - (Carboxamido) - phenylacetamido-penicillins PFIZER Inc 30 Nov 1972 [28 Jan 1972] 55458/72 Heading C2C Novel α-carboxamidobenzylpenicillin compounds having the general Formula (III) wherein R 1  is C 1-4  alkyl; substituted C 1-4  alkyl wherein the substituent is carboxy, carbamyl, cyano, chlorine, bromine, C 1-3  alkoxy or C 1-3  alkylthio; Z is -O-, or -SO 2 -; and R 2  is hydrogen or 1-(C 2-5 )- alkanoyloxy-(C 1-4 )alkyl, and base salts thereof when the penicillin is an acid, are prepared (1) when Z is -O-, by reacting a compound of formula (I) wherein R 2  is alkanoyloxyalkyl as defined above, with N-hydroxysuccinimide in the presence of a carbodiimide to give a novel intermediate of Formula (II) and reacting this compound with an O-substituted hydroxylamine of formula: in which R 1  is as previously defined, to give the required compound (III) in which R 2  is alkanoyloxyalkyl, and if desired, hydrolysing to convert R 2  to hydrogen and optionally converting the resulting acid into a base salt; and (2) when Z in the compound (III) is or -SO 2 -, by reacting the aforesaid compound (I) with an alkanoyl- or alkylsulphonylisocyanate of formula: R 1 -Z-N = C =O wherein R 1  is as defined above except that when R 1  is carboxy alkyl the carboxy group is esterified with benzyl alcohol or an alkanol, and when so, subsequently debenzylating or dealkylating the product, and if desired, hydrolysing the product to convert R 2  to hydrogen and optionally converting the resulting acid into a base salt. The compounds (III) have antibacterial activity, and may be made up into antibiotic pharmaceutical compositions by formulating with a pharmaceutical carrier or diluent. Various examples are given for producing starting materials and intermediates, as follows: compounds of Formula (I) above are prepared by esterifying 6-aminopenicillanic acid with an alkanoyloxyalkyl halide, and N-acylating the ester with phenylmalonic mono-acid chloride. Alkanoyloxyalkyl halides are prepared by reacting aldehydes with various acyl halides. Numerous O - substituted hydroxylamines of formula: H 2 N-O-R 1  and alkanoyl- and alkylsulphonyl isocyanates of formulµ and R 1 -SO 2 -N =C=O respectively, where R 1  is as defined above, are prepared. Methoxyethoxyamine is prepared by reacting 2-phthalimidooxyethyl bromide with sodium methoxide to give 2-methoxyphthalimidooxyethane, which is reacted with hydrochloric acid to give the salt of the required amine, the free amine then being obtained by treatment with sodium hydroxide.
Chronic constipation is a common problem in childhood, accounting for almost 3% of consultations in pediatric practice. In many children constipation is accompanied by overflow soiling (fecal incontinence). This condition often gives rise to behavioral, social, and emotional problems.

We plan to develop a disease-specific instrument to assess HRQoL in children with constipation and fecal incontinence. We hypothesize that HRQoL is worse in children with fecal incontinence compared to children with constipation but no fecal incontinence. The instrument will involve both parent and child self-reporting measures and will enable researchers to evaluate how disease and treatment strategies impact both child and parent perceptions of quality of life. In the long run this will enable physicians to develop a child friendly approach to management of chronic constipation and fecal incontinence.
AIM: Congenital Zika Virus Syndrome (CZS) presents notable hurdles to neurodevelopment, with language development emerging as a crucial aspect. This study investigates sleep patterns and language skills in children with CZS, aiming to explore the potential synchronization of sleep development with their neurodevelopment.
METHOD: We studied cross-sectionally 135 children with CZS aged 0 to 48 months, investigating sleep using the BISQ Questionnaire. Language development was assessed using the Early Language Milestone Scale, while motor development and cognitive and social ability were assessed using the Bayley Scales of Infant and Young Child Development 3rd edition. We also studied longitudinally a cohort of 16 children (initially aged 0 to 12 months) whom we followed for four years, assessing at one-year intervals.
RESULTS: Sleep disturbances and language deficits were highly frequent in this population. In the 0-12 months group, a late bedtime and frequent nighttime awakenings were associated with poorer auditory expressive skills. At 13-24 months, nighttime awakenings were associated with poorer auditory expressive skills, while among 25-36-month-olds decreased auditory receptive skills were associated with longer sleep onset latency and reduced nighttime sleep duration.
CONCLUSION: The brain alterations caused by Zika virus infection affect both sleep disturbances and delays in language development. It is possible that sleep disturbance may be a mediating factor in the pathway between CZS and delayed language development, as the three analyzed language skills showed a correlation with sleep parameters.
The invention belongs to the technical field of biological medicines, and particularly discloses a new application of Areg. Application of Areg expressed preparation or Areg protein in preparing medicine for preventing and treating myocardial infarction is provided. The application of an Areg expression promoting preparation or Areg protein in preparing a medicament for preventing and treating cardiac dysfunction is provided. Use of an agent that inhibits Areg expression in the preparation of a myocardial infarction biological model or a ventricular adverse remodeling biological model. Use of a formulation for detecting the expression level of Areg for the preparation of a product for screening (diagnosing) myocardial infarction. The invention finds that the Areg protein expression is increased after myocardial infarction of mice, and also finds that knockout of Areg aggravates ventricular adverse remodeling after myocardial infarction of mice. And it is verified that the autophagosome formation is inhibited by increasing the expression level of the Areg protein, so that the myocardial cell apoptosis is reduced, the loss of functional myocardial cells is reduced, the ventricular remodeling is improved, and the heart function is protected.
The subject will receive one IV infusion of ferumoxytol administered as 1020 mg over 30 minutes or an equivalent volume of normal saline. At the time of the infusion, the patient will also be given an opaque bottle, containing either vitamin C tablets or ferrous sulfate 325 mg.
Cancer cachexia is characterized by a hypermetabolic state that leads to catabolism that is responsible for reductions in lean mass.These catabolic changes are accompanied by an increase in total energy expenditure, but a decrease in voluntary energy expenditure that ultimately results clinically in cachexia and its symptoms of lethargy, fatigue, weakness and general malaise (Kotler DP. Cachexia. Ann Intern Med. 2000; 133:622-634).

The prevalence of cachexia increases from 50 percent at presentation to more than 80 percent before death from malignancy. In over 20 percent of cancer patients, cachexia is the cause of death (Bruera E. Anorexia, cachexia and nutrition. Br Med J 1997;315:1219-1222). Cancer cachexia leads to shorter survival, decreased response rates and increased toxicity to chemotherapy, weakness, and an overall decreased quality of life (DeWys et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980 Oct;69(4):491-7). The purpose of this study is to assess the efficacy of GTx-024 on total body lean mass. Secondary endpoints include but are not limited to assessment of GTx-024 on muscle function, total body weight and total body fat mass.
OBJECTIVES: I. Determine whether patients with surgically debulked ovarian epithelial cancer develop delayed-type hypersensitivity to dinitrophenyl-modified autologous tumor vaccine. II. Assess the toxic effects of this regimen in these patients. III. Determine the feasibility of conducting a group wide vaccine study.

OUTLINE: Patients undergo a standard debulking procedure with the tumor tissue being sent to Thomas Jefferson University. Patients then receive six courses of combination chemotherapy consisting of either paclitaxel and cisplatin or paclitaxel and carboplatin. Vaccine therapy must commence within 4-12 weeks of completion of chemotherapy. Patients are tested for delayed-type hypersensitivity (DTH) on day -7. Cyclophosphamide IV is administered on day 0. Dinitrophenyl (DNP)-modified autologous ovarian epithelial cell vaccine and BCG adjuvant are injected once a week beginning on day 3 and continuing for 6 weeks. DTH testing is repeated at week 8. Booster vaccine injections are administered at 6 and 12 months if patient is disease free. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: Approximately 20 patients will be accrued for this study.
The invention relates to anti-AIDS nanometer Chinese medicine and a production method thereof. The anti-AIDS nanometer Chinese medicine comprises the following raw material composition of active ingredients in percentage by weight: dozens of kinds of Chinese medicine such as 40 to 50 of trichosanthin, 30 to 40 of scrophulariaceae, 30 to 40 of coptis, 40 to 50 of scutellaria and the like. The method comprises the production processes of pretreatment pulverization, high-frequency ultrasonic pulverization extraction dispersion, microwave leaching, supersonic speed spray drying pulverization, nanometer grinding, mixing, capsule filling and sterilization. The recipe has the antivirus and antitumor treatment effect, has no toxic or side effect, and is applicable to the treatment on tumor patients and patients with viruses such as HIV, HBV and the like. Through diagnosis and treatment, efficacy analysis, drug tropism, yin and yang identify identification, body resistance strengthening and evil eliminating, reasonable compatibility of assistant and guide medicine and the like, the recipe is divided into four preparations: a monitoring preparation, a noon preparation, an evening preparation and a night preparation which are respectively taken in four time intervals. The anti-AIDS nanometer Chinese medicine can also be used for local skin application and acupuncture point medication percutaneous absorption treatment on human bodies according to different periods.
BACKGROUND: Around 10% of fractures lead to complications. With increasing fracture incidences in recent years, this poses a serious burden on the healthcare system, with increasing costs for treatment. In the present study, we aimed to identify potential 'new' blood markers to predict the development of post-surgical complications in trauma patients following a fracture.
METHODS: A total of 292 trauma patients with a complete three-month follow-up were included in this cohort study. Blood samples were obtained from 244 of these patients. Two complication groups were distinguished based on the Clavien-Dindo (CD) classification: CD grade I and CD grade III groups were compared to the controls (CD 0). The Mann-Whitney U test was used to compare the complication groups to the control group.
RESULTS: Analysis of the patients' data revealed that risk factors are dependent on sex. Both, males and females who developed a CD III complication showed elevated blood levels of B7-1 (p = 0.015 and p = 0.018, respectively) and PlGF-1 (p = 0.009 and p = 0.031, respectively), with B7-1 demonstrating greater sensitivity (B7-1: 0.706 (male) and 0.692 (female), PlGF-1: 0.647 (male) and 0.615 (female)). Further analysis of the questionnaires and medical data revealed the importance of additional risk factors. For males (CD 0: 133; CD I: 12; CD III: 18 patients) alcohol consumption was significantly increased for CD I and CD III compared to control with p = 0.009 and p = 0.007, respectively. For females (CD 0: 107; CD I: 10; CD III: 12 patients) a significantly increased average BMI [kg/m2] from 25.5 to 29.7 with CD III was observed, as well as an elevation from one to three comorbidities (p = 0.003).
CONCLUSIONS: These two potential new blood markers hold promise for predicting complication development in trauma patients. Nevertheless, further studies are necessary to evaluate the diagnostic utility of B7-1 and PlGF-1 in predicting complications in trauma patients and consider sex differences before their possible use as routine clinical screening tools.
To assess the effect of defocus incorporated multiple segments (DIMS) (Miyosmart) lenses on myopic progression in children not responding to low-concentration atropine (LCA) (0.01%) eye drops. A total of 10 children not responding to LCA (0.01%) eye drops were advised to start using the DIMS lens to halt the progression of myopia. The children were followed for a period of 1 year. Eight out of 10 children showed a reduction in the progression of myopia. Pre DIMS, the progression was -0.68 D ± 0.3 D sph, which reduced to -0.24 ± 0.2 diopter progression post DIMS lens in the eight children. The remaining two children still progressed by -0.57 ± 0.4 D sph over a year. The axial length growth reduced from 0.28 ± 0.3 mm to 0.16 ± 0.2 mm after using the DIMS lens in these non-responders. The DIMS lens shows initial promise in reducing the progression of myopia even in children not responding to LCA 0.01% eye drops.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to surgery, proctology. Two purse string sutures are applied without overlap of stitches proximal to the zone of thrombosed nodes by 5 cm in the area of ​​unchanged mucous membrane in the horizontal direction, with stitches up to 1.5 cm long and 1 cm apart. In this case, the first suture is applied clockwise, bringing the ends of the threads to 00 o'clock relative to the conventional dial, the second seam is applied counterclockwise at a distance of 0.4-0.5 mm from the first seam, bringing the ends of the threads at 3-00 o'clock relative to the conventional dial. The head of the hemorrhoidal stapler is introduced through the area sewn with purse-string sutures. The seams are tied in such a way that the seams cover the working rod of the apparatus under the head. Delayed stitching of the rectal wall is performed with a pause of 30 s. Reserved mucosa is removed from the rectum. The anoderm is punctured, followed by squeezing out the thrombotic masses until the node is completely emptied. A piece of hemostatic sponge moistened with liquid betadine is introduced through the puncture into the lumen of the node. In the postoperative period, enteral mixtures are used for postoperative nutrition for 7 days as the only source of nutrition.EFFECT: method provides a good cosmetic and functional result of the operation, does not require dressings and local treatment, allows to reduce the period of rehabilitation after surgery, is low-traumatic, and reduces possible complications.1 cl, 3 dwg, 2 ex
Metyrosine inhibits tyrosine hydroxylase, which catalyzes the first transformation in catecholamine biosynthesis, i.e. the conversion of tyrosine to dihydroxyphenylalanine (DOPA). Because the first step is also the rate-limiting step, blockade of tyrosine hydroxylase activity results in decreased endogenous levels of catecholamines, usually measured as decreased urinary excretion of catecholamines and their metabolites.

In patients with pheochromocytoma, who produce excessive amounts of norepinephrine and epinephrine, administration of one gram to four grams of metyrosine per day has reduced catecholamine biosynthesis from about 35% to 80% as measured by the total excretion of catecholamines and their metabolites (metanephrine and vanillylmandelic acid). The maximum biochemical effect usually occurs within two to three days, and the urinary concentration of catecholamines and their metabolites usually returns to pre-treatment levels within three to four days after metyrosine is discontinued. In some patients the total excretion of catecholamines and catecholamine metabolites may be lowered to normal or near normal levels (less than 10 mg/24 hours). In most patients the duration of treatment has been two to eight weeks, but several patients have received metyrosine for periods of 1 to 10 years. Most patients with pheochromocytoma treated with metyrosine experience decreased frequency and severity of hypertensive attacks with their associated headache, nausea, sweating, and tachycardia. In patients who respond, blood pressure decreases progressively during the first two days of therapy with metyrosine; after withdrawal, blood pressure usually increases gradually to pre-treatment values within two to three days.

Metyrosine is well absorbed from the gastrointestinal tract. From 53% to 88% (mean 69%) was recovered in the urine as unchanged drug following maintenance oral doses of 600 mg to 4000 mg/24 hours in patients with pheochromocytoma or essential hypertension. Less than 1% of the dose was recovered as catechol metabolites. These metabolites are probably not present in sufficient amounts to contribute to the biochemical effects of metyrosine. The quantities excreted, however, are sufficient to interfere with accurate determination of urinary catecholamines determined by routine techniques.

Plasma half-life of metyrosine determined over an 8-hour period after single oral doses was 3 to 3.7 hours in three patients.

For further information, refer to: Sjoerdsma A, Engelman K, Waldman TA, Cooperman LH, Hammond WG. Pheochromocytoma: Current Concepts of Diagnosis and Treatment: Combined Clinical Staff Conference at the National Institutes of Health. Ann Intern Med. 1966;65:1302-1326.